Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Rating of “Moderate Buy” by Analysts

Exact Sciences Co. (NASDAQ:EXAS) has received an average rating of “Moderate Buy” from the eighteen research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $72.94.

EXAS has been the topic of several recent analyst reports. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a report on Thursday, November 21st. Canaccord Genuity Group cut their price target on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Evercore ISI decreased their price target on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Robert W. Baird dropped their price objective on Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Citigroup reduced their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $56.50 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The firm has a market cap of $10.46 billion, a PE ratio of -48.29 and a beta of 1.24. The firm has a 50 day simple moving average of $57.82 and a 200-day simple moving average of $58.88. Exact Sciences has a 1-year low of $40.62 and a 1-year high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The business had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. On average, equities analysts expect that Exact Sciences will post -1.13 EPS for the current year.

Insider Transactions at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were acquired at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the transaction, the chief executive officer now owns 1,074,191 shares in the company, valued at $55,159,707.85. The trade was a 1.85 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.36% of the company’s stock.

Institutional Investors Weigh In On Exact Sciences

Hedge funds have recently bought and sold shares of the business. Huntington National Bank raised its position in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 352 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Exact Sciences in the second quarter worth $29,000. RPg Family Wealth Advisory LLC acquired a new stake in Exact Sciences in the third quarter valued at $34,000. Capital Performance Advisors LLP bought a new position in Exact Sciences during the 3rd quarter valued at $35,000. Finally, Modus Advisors LLC acquired a new position in Exact Sciences during the 4th quarter worth $43,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.